Horizon Pharma PLC (HZNP) Given Consensus Recommendation of “Buy” by Analysts
Shares of Horizon Pharma PLC (NASDAQ:HZNP) have been assigned an average recommendation of “Buy” from the fifteen analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and ten have given a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $17.82.
A number of research analysts have issued reports on HZNP shares. Cantor Fitzgerald started coverage on Horizon Pharma PLC in a research report on Friday, June 16th. They set an “overweight” rating and a $13.00 price target for the company. BidaskClub upgraded Horizon Pharma PLC from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. Zacks Investment Research upgraded Horizon Pharma PLC from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 11th. Jefferies Group LLC reiterated a “buy” rating and set a $14.00 price target on shares of Horizon Pharma PLC in a research report on Friday, July 14th. Finally, Piper Jaffray Companies set a $17.00 price target on Horizon Pharma PLC and gave the stock a “buy” rating in a research report on Tuesday, July 25th.
Institutional investors have recently made changes to their positions in the company. Morgan Stanley lifted its holdings in shares of Horizon Pharma PLC by 59.7% in the first quarter. Morgan Stanley now owns 1,422,666 shares of the biopharmaceutical company’s stock valued at $21,027,000 after buying an additional 531,882 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Horizon Pharma PLC by 82.8% in the second quarter. Russell Investments Group Ltd. now owns 153,668 shares of the biopharmaceutical company’s stock valued at $1,824,000 after buying an additional 69,626 shares during the period. Neuberger Berman Group LLC acquired a new stake in shares of Horizon Pharma PLC in the second quarter valued at $7,147,000. Bank of New York Mellon Corp lifted its holdings in shares of Horizon Pharma PLC by 19.7% in the second quarter. Bank of New York Mellon Corp now owns 915,421 shares of the biopharmaceutical company’s stock valued at $10,866,000 after buying an additional 150,850 shares during the period. Finally, Wellington Management Group LLP acquired a new stake in shares of Horizon Pharma PLC in the first quarter valued at $730,000. Institutional investors and hedge funds own 82.32% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Horizon Pharma PLC (HZNP) Given Consensus Recommendation of “Buy” by Analysts” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/10/11/horizon-pharma-plc-hznp-given-consensus-recommendation-of-buy-by-analysts.html.
Horizon Pharma PLC (NASDAQ HZNP) traded up 0.693% on Wednesday, reaching $13.795. 1,111,030 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $13.03 and a 200-day moving average of $12.71. Horizon Pharma PLC has a one year low of $9.45 and a one year high of $21.98. The stock’s market cap is $2.25 billion.
Horizon Pharma PLC (NASDAQ:HZNP) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.29. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. The company had revenue of $289.51 million during the quarter, compared to analyst estimates of $237.01 million. During the same quarter in the previous year, the firm posted $0.56 EPS. The firm’s quarterly revenue was up 12.5% on a year-over-year basis. Equities research analysts forecast that Horizon Pharma PLC will post $1.07 EPS for the current fiscal year.
Horizon Pharma PLC Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.